15
Participants
Start Date
September 30, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2017
IXO regimen
"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
The Ottawa Hospital Cancer Centre, Ottawa
Lead Sponsor
Collaborators (1)
Ottawa Regional Cancer Foundation
UNKNOWN
Sanofi
INDUSTRY
Hoffmann-La Roche
INDUSTRY
Ottawa Hospital Research Institute
OTHER